Navigation Links
Cyberonics To Report Fiscal Year 2013 Second Quarter Results And Host Webcast And Conference Call On November 16, 2012
Date:11/1/2012

HOUSTON, Nov. 1, 2012 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX) today announced that the company will report financial results for the second quarter ended October 26, 2012, of its fiscal year ending April 26, 2013, on Friday, November 16, 2012, before regular market trading hours.  The company will conduct a conference call to discuss those results on the same day at 8:00 AM Central Time (9:00 AM Eastern Time).

Fiscal Year 2013 Second Quarter Results Webcast and Conference Call Instructions
The conference call will be available to interested parties through a live audio webcast in the Investor Relations section of Cyberonics' corporate website at http://www.cyberonics.com.  To listen to the conference call live by telephone dial 877-638-4557 (if dialing from within the U.S.) or 914-495-8522 (if dialing from outside the U.S.).  The conference ID is 40126804. 

Within 24 hours of the webcast, a replay will be available under the "Events & Presentations" section of the Investor Relations portion of the Cyberonics website, where it will be archived and accessible for approximately 12 months.

About Cyberonics, Inc. and the VNS Therapy® System
Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation.  The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression.  The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.

Contact Information
'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cyberonics To Report Fiscal Year 2013 First Quarter Results And Host Conference Call On August 28, 2012
2. Cyberonics To Present At Morgan Stanley 2012 Global Healthcare Conference
3. Cyberonics To Participate In Upcoming September Investor Conferences
4. Cyberonics Announces Investment In cerbomed GmbH
5. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
6. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
7. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
8. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
9. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
10. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
11. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)...  Actavis plc (NYSE: ACT ) announced ... Food and Drug Administration (FDA) as a twice-daily, ... syndrome with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed ... agonist, a delta receptor antagonist, and a kappa ... "The FDA,s approval of VIBERZI ...
(Date:5/27/2015)... May 27, 2015   Madison Laser Tattoo Removal ... Madison and the surrounding area to offer ... Madison Laser Tattoo Removal is dedicated to bringing a solution ... Wisconsin . "I founded Madison Laser Tattoo ... and return their skin to its natural look," said ...
(Date:5/27/2015)...  Sequenom, Inc. (NASDAQ: SQNM ), a life ... development of innovative products and services, today announced that ... laboratory operations in Grand Rapids, Michigan ... , North Carolina.  Sequenom Laboratories, cystic fibrosis carrier ... North Carolina laboratory location.  ...
Breaking Medicine Technology:Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 2Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 3Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 4Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 5Madison Laser Tattoo Removal Brings Superior Laser Tattoo Removal Services To Madison, WI With Astanza Duality 2Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities 2Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities 3
(Date:5/27/2015)... 2015 Hundreds of Risperdal lawsuits ... individuals who allegedly suffered gynecomastia (male breast growth) ... the antipsychotic drug continue to move forward in ... Philadelphia Court of Common Pleas. According to court ... trial program, as the third trial involving Risperdal’s ...
(Date:5/27/2015)... Texas (PRWEB) May 27, 2015 In ... are getting tighter, it can be challenging for doctors ... for cutting edge treatments. , Austin-based HealthTronics, ... with minimally invasive, mobile medical therapies for clinically sophisticated ... portfolio with the acquisition of Laser Ventures, Inc ...
(Date:5/27/2015)... NOVAtime Technology, Inc. ( http://www.novatime.com ... for enterprise organizations, announced today that SanMar Corporation ... its time, attendance and point tracking processes for ... United States. , Family-owned since 1971, Seattle-based ... retail, private label, and mill brands. SanMar supplies ...
(Date:5/27/2015)... Little Rock, AR (PRWEB) May 27, 2015 ... and Medix today announce a partnership to provide ... the Medix community. This collaboration seeks to strengthen ... skills measurement through CMSA’s CKP program. The mutually ... focused on identifying individual skills of talent in ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 CompanionDx ... pharmacogenomic and somatic genomic analysis in personalized cancer therapy: ... by the American Society of Clinical Oncology (ASCO) as ... 2 in Chicago. , The molecular and clinical data ... Genome Atlas (TCGA) database. The study reports improved patient ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 3Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 2Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 3Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3
... Ltd, a Pune-based company have jointly come out with ... this at a press conference here on Thursday,// NCL ... the chirally pure S-Amlodipine, a product of their collaborative ... suffering from hypertension. ,Stating that Emcure is ...
... that has receive only a little scientific interest and virtually ... and respiratory health. A study of over 2,000 children ... issue. The study appeared in the January 15, 2002 ... and potassium intakes were associated with lower lung function. ...
... company has finalized development of a digital screening ... of diagnosing melanomas, the third most common cancer ... said that in terms of its ability to ... analysis and computer-aided diagnostic software for SolarScan, which ...
... France observed in a study that red wine drinkers ... "good" cholesterol. This helps show some light on why ... disease. // ,Researchers compared HDL cholesterol levels between ... who are regular drinkers and those who are heavy ...
... at the University of Michigan, made a new study ... patients after head and neck surgery. Ann Arbor say leeches ... who have surgery// to remove cancer in and around the ... ,Doctors say about 15 percent of patients develop obstructions ...
... recall test is able to differentiate those who will get ... a condition of older people - so we can expect ... ages.// Treatments are now available and they seem to work ... a priority. ,Researchers at the University of Toronto ...
Cached Medicine News:Health News:Latest device for identifying Melanomas 2
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
For the qualitative detection of group A Streptococcal antigen from throat swabs...
Medicine Products: